An Effectiveness, Safety and Quality of Life Measures With Hydromorphone HCL, Dilaudid CR (Controlled Release)
Status:
Completed
Trial end date:
2001-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to characterize the effectiveness and safety of OROS
hydromorphone HCL and OxyContin in patients with chronic osteoarthritis (OA) of the knee or
hip who are receiving chronic nonsteroidal anti-inflammatory drug (NSAID) or other
nonsteroidal, non-opioid analgesic (ie, acetaminophen or aspirin) therapy.